US · guidance
CMS Pub. 100-03, ch. 1, § 230.9
Cryosurgery of Prostate
CIM 35-96
Cryosurgery of the prostate gland, also known as cryosurgical ablation of the prostate (CSAP), destroys
prostate tissue by applying extremely cold temperatures in order to reduce the size of the prostate gland. It is
safe and effective, as well as medically necessary and appropriate, as primary treatment for patients with
clinically localized prostate cancer, Stages T1-T3.
Cryosurgery of the prostate as a salvage therapy is not covered for any services performed prior to June 30,
2001.
Salvage Cryosurgery Of Prostate After Radiation Failure. Salvage cryosurgery of the prostate for recurrent
cancer is medically necessary and appropriate only for those patients with localized disease who:
1. Have failed a trial of radiation therapy as their primary treatment; and
2. Meet one of the following conditions: Stage T2B or below, Gleason score < 9, PSA < 8 ng/mL.
Cryosurgery as salvage therapy is therefore not covered under Medicare after failure of other therapies as the
primary treatment. Cryosurgery as salvage is only covered after the failure of a trial of radiation therapy,
under the conditions noted above.
History
(Rev. 1, 10-03-03)
Provenance
- Source
- cms.gov
- Retrieved
- 2026-08-25
- Edition
- iom-2026-08-25
- Content hash
4d9bfe81cbff6c60965550d22a2e1edc8ccdbef7e1c7b333da533533fcb12ea9
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.